Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings

Dow Jones

Yesterday

0740 GMT - Innovent Biologics' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2667656833"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2667656833\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2667656833?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-14 15:40","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2667656833","market":"fut","top_or_hot":-1,"title":"Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0740 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Innovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nInnovent's Enlarged Cash Holdings, Investment Fair Value Could Boost Earnings\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2026-09-14 15:40</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>0740 GMT - <a href=\"https://laohu8.com/S/IVBIY\">Innovent Biologics</a>' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000165453.HKD","symbol_name":"华夏精选大中华科技基金 A类港币","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2667656833","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2667656833","pubTimestamp":1789371600,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0740 GMT - Innovent Biologics' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"HK0000165453.HKD":"华夏精选大中华科技基金 A类港币","LU2097828714.EUR":"AZ EQUITY CHINA \"BAZ\" (EUR) ACC","LU0149534421.HKD":"SCHRODER ISF HONG KONG EQ \"A\" ACC","LU0463099449.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) ACC","LU2097828805.USD":"AZ EQUITY CHINA \"A-AZ\" (USD) ACC","LU1969619763.USD":"EASTSPRING INV CHINA A SHARES GROWTH \"A\" (USD) ACC","LU0502904849.HKD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (HKD) ACC","BK1583":"高瓴概念","LU0607220059.USD":"SCHRODER ISF HONG KONG EQUITY \"A\" (USD) ACC","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H","LU2097828474.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC A","01801":"信达生物","LU2242644610.SGD":"Fidelity China Innovation A-ACC-SGD","LU1188198961.HKD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" (HKD) INC QV","BK1589":"北水核心资产","LU0244354667.USD":"SCHRODER ISF CHINA OPPORTUNITIES \"A\" ACC","LU0455707207.USD":"FIDELITY FUNDS  CHINA INNOVATION \"A\" (USD) INC","LU2328871848.SGD":"Eastspring Investments - China A Shares Growth AS SGD","BK1161":"生物科技","LU1831875114.USD":"SCHRODER ISF ALL CHINA EQUITY \"A\" (USD) ACC","LU2488822045.USD":"ALLIANZ CHINA HEALTHY LIVING \"AT\" (USD) ACC","LU2097828557.USD":"AZ EQUITY CHINA \"A\" (USD) ACC","KURE":"KraneShares MSCI All China Health Care Index ETF","LU2097828631.EUR":"AZ EQUITY CHINA \"A\" (EUR) ACC"},"translate_title":"信达扩大现金持有量，投资公允价值可能会提高盈利","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"KURE":0.6,"01801":1.95},"content_text":"0740 GMT - Innovent Biologics' enlarged cash holdings and investment fair-value gains could bolster its earnings over 2026-2028, say DBS Group Research analysts in a note. The Chinese biopharmaceutical company's fair value of its investments such as wealth products increased in 1H, while its total cash is expected to rise to 29 billion yuan in December 2028 from 20 billion yuan in December 2025, they say. DBS raises its annual interest income projections by 76% over 2026-2028. It also lifts its 2026-2028 earnings estimates by 6%-21%. DBS reiterates its buy rating and 144.00 Hong Kong dollar target price on the stock. Shares are up 3.4% at HK$96.75.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":true,"need_login_tip":false,"code":"91000000","status":"200"}}}